Evolent Health (EVH) Projected to Post Earnings on Tuesday

Evolent Health (NYSE:EVH) is projected to post its Q4 2025 results after the market closes on Tuesday, February 24th. Analysts expect Evolent Health to post earnings of $0.06 per share and revenue of $468.4810 million for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 5:00 PM ET.

Evolent Health Stock Up 0.5%

Shares of NYSE EVH opened at $2.79 on Monday. The stock has a market capitalization of $310.81 million, a PE ratio of -1.76 and a beta of 0.27. The company has a quick ratio of 1.33, a current ratio of 1.33 and a debt-to-equity ratio of 1.25. The firm has a fifty day moving average of $3.59 and a 200-day moving average of $5.97. Evolent Health has a 52-week low of $2.56 and a 52-week high of $12.06.

Institutional Investors Weigh In On Evolent Health

A number of large investors have recently added to or reduced their stakes in EVH. CIBC Private Wealth Group LLC lifted its holdings in Evolent Health by 4,000.0% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,100 shares of the technology company’s stock worth $35,000 after buying an additional 4,000 shares in the last quarter. Strs Ohio acquired a new stake in shares of Evolent Health during the first quarter valued at about $47,000. Vise Technologies Inc. purchased a new stake in shares of Evolent Health during the fourth quarter worth about $50,000. Headlands Technologies LLC acquired a new position in shares of Evolent Health in the second quarter worth about $58,000. Finally, RPO LLC purchased a new position in Evolent Health in the fourth quarter valued at about $71,000.

Wall Street Analyst Weigh In

EVH has been the subject of a number of research reports. Truist Financial lowered their price target on Evolent Health from $16.00 to $10.00 and set a “buy” rating for the company in a research report on Monday, November 10th. Zacks Research upgraded Evolent Health from a “strong sell” rating to a “hold” rating in a report on Monday, November 10th. Citigroup dropped their target price on shares of Evolent Health from $9.50 to $6.00 and set a “buy” rating for the company in a research report on Friday, January 9th. Oppenheimer cut their price target on shares of Evolent Health from $18.00 to $12.00 and set an “outperform” rating on the stock in a report on Wednesday, November 12th. Finally, Piper Sandler set a $6.00 price objective on shares of Evolent Health in a research note on Tuesday, December 2nd. Twelve analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $9.50.

Evolent Health Company Profile

Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company’s core offerings include care management solutions, population health analytics and clinical advisory services.